John D Seeger
Overview
Explore the profile of John D Seeger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
2280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brookhart M, Mayne T, Coombs C, Breskin A, Ness E, Bessonova L, et al.
Hepatology
. 2024 Dec;
PMID: 39630028
Background And Aims: Primary biliary cholangitis is a rare, progressive liver disease. Obeticholic acid (OCA) received accelerated approval for treating patients with primary biliary cholangitis in whom ursodeoxycholic acid failed,...
2.
de Vogel S, Seeger J, Arana A, Margulis A, McQuay L, Perez-Gutthann S, et al.
Pharmacoepidemiol Drug Saf
. 2024 Apr;
33(5):e5799.
PMID: 38680102
Background: Many factors contribute to developing and conducting a successful multi-data source, non-interventional, post-authorization safety study (NI-PASS) for submission to multiple health authorities. Such studies are often large undertakings; evaluating...
3.
Ogilvie R, Layton J, Lloyd P, Jiao Y, Djibo D, Wong H, et al.
BMC Pediatr
. 2024 Apr;
24(1):276.
PMID: 38671379
Background: COVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. This study's objective was to estimate the effectiveness...
4.
Hu M, Shoaibi A, Feng Y, Lloyd P, Wong H, Smith E, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e248192.
PMID: 38656578
Importance: Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes that may not be identified in prelicensure trials. Objective: To conduct near-real-time monitoring of health...
5.
Lloyd P, Lufkin B, Moll K, Ogilvie R, McMahill-Walraven C, Beachler D, et al.
Vaccine
. 2024 Feb;
42(8):2004-2010.
PMID: 38388240
Background: Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance systems. TTS incidence rates (IRs) in the United States (U.S.)...
6.
Layton J, Peetluk L, Wong H, Jiao Y, Djibo D, Bui C, et al.
Vaccine X
. 2024 Feb;
16:100447.
PMID: 38318230
Background: Monovalent booster/additional doses of COVID-19 vaccines were first authorized in August 2021 in the United States. We evaluated the real-world effectiveness of receipt of a monovalent booster/additional dose of...
7.
Cocoros N, Gurwitz J, Cziraky M, Granger C, Harkins T, Haynes K, et al.
Clin Trials
. 2023 Jun;
20(4):416-424.
PMID: 37322894
Background: There are unique opportunities related to the design and conduct of pragmatic trials embedded in health insurance plans, which have longitudinal data on member/patient demographics, dates of coverage, and...
8.
Hu M, Wong H, Feng Y, Lloyd P, Smith E, Amend K, et al.
JAMA Pediatr
. 2023 May;
177(7):710-717.
PMID: 37213095
Importance: Active monitoring of health outcomes after COVID-19 vaccination offers early detection of rare outcomes that may not be identified in prelicensure trials. Objective: To conduct near-real-time monitoring of health...
9.
Schneider K, Bell E, Zhou C, Yang G, Lloyd P, Clarke T, et al.
JAMA Netw Open
. 2023 May;
6(5):e2313512.
PMID: 37191962
Importance: Safety and effectiveness studies of COVID-19 vaccines are being conducted using clinical data, including administrative claims. However, claims data only partially capture administered COVID-19 vaccine doses for numerous reasons,...
10.
Chomistek A, Phiri K, Doherty M, Calderbank J, Chiuve S, McIlroy B, et al.
Drug Saf
. 2023 Mar;
46(5):515.
PMID: 36964331
No abstract available.